Wael Naboulsi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wael Naboulsi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Sitek
Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
2 shared publications - Dominik Andre Megger
Medizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany
2 shared publications Frank Weber
Department of General, Visceral and Transplantation Surgery, University of Duisburg-Essen, University Hospital Essen, 45147 Essen, Germany
2 shared publicationsHelmut E. Meyer
Medizinisches Proteom-Center, Ruhr-Universität Bochum, 44801 Bochum, Germany
2 shared publicationsHideo A. Baba
Institute of Pathology, University of Duisburg-Essen, University Hospital Essen, 45147 Essen, Germany
2 shared publicationsMartin Eisenacher
Medizinisches Proteom-Center, Ruhr-Universität Bochum, 44801 Bochum, Germany
2 shared publications
Latest Publications
- 1 November 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1864 (11) , 1579-1585
Quantitative proteome analysis reveals the correlation between endocytosis-associated proteins and hepatocellular carcinoma dedifferentiation
- 1 November 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Vol. 1864 (11) , 1579-1585
Quantitative proteome analysis reveals the correlation between endocytosis-associated proteins and hepatocellular carcinoma dedifferentiation
- 18 December 2015
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 15 (1) , 38-47
Quantitative Tissue Proteomics Analysis Reveals Versican as Potential Biomarker for Early-Stage Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most aggressive tumors, and the treatment outcome of this disease is improved when the cancer is diagnosed at an early stage. This requires biomarkers allowing an accurate and early tumor diagnosis. To identify potential markers for such applications, we analyzed a patient cohort consisting of 50 patients (50 HCC and 50 adjacent nontumorous tissue samples as controls) using two independent proteomics approaches. We performed label-free discovery analysis on 19 HCC and corresponding tissue samples. The data were analyzed considering events known to take place in early events of HCC development, such as abnormal regulation of Wnt/b-catenin and activation of receptor tyrosine kinases (RTKs). 31 proteins were selected for verification experiments. For this analysis, the second set of the patient cohort (31 HCC and corresponding tissue samples) was analyzed using selected (multiple) reaction monitoring (SRM/MRM). We present the overexpression of ATP-dependent RNA helicase (DDX39), Fibulin-5 (FBLN5), myristoylated alanine-rich C-kinase substrate (MARCKS), and Serpin H1 (SERPINH1) in HCC for the first time. We demonstrate Versican core protein (VCAN) to be significantly associated with well differentiated and low-stage HCC. We revealed for the first time the evidence of VCAN as a potential biomarker for early-HCC diagnosis.
- 18 December 2015
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 15 (1) , 38-47
Quantitative Tissue Proteomics Analysis Reveals Versican as Potential Biomarker for Early-Stage Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most aggressive tumors, and the treatment outcome of this disease is improved when the cancer is diagnosed at an early stage. This requires biomarkers allowing an accurate and early tumor diagnosis. To identify potential markers for such applications, we analyzed a patient cohort consisting of 50 patients (50 HCC and 50 adjacent nontumorous tissue samples as controls) using two independent proteomics approaches. We performed label-free discovery analysis on 19 HCC and corresponding tissue samples. The data were analyzed considering events known to take place in early events of HCC development, such as abnormal regulation of Wnt/b-catenin and activation of receptor tyrosine kinases (RTKs). 31 proteins were selected for verification experiments. For this analysis, the second set of the patient cohort (31 HCC and corresponding tissue samples) was analyzed using selected (multiple) reaction monitoring (SRM/MRM). We present the overexpression of ATP-dependent RNA helicase (DDX39), Fibulin-5 (FBLN5), myristoylated alanine-rich C-kinase substrate (MARCKS), and Serpin H1 (SERPINH1) in HCC for the first time. We demonstrate Versican core protein (VCAN) to be significantly associated with well differentiated and low-stage HCC. We revealed for the first time the evidence of VCAN as a potential biomarker for early-HCC diagnosis.